Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant, first-line, and adjuvant treatment for certain advanced HER2 ...

(pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early, or locally advanced breast cancer as part of a complete treatment regimen. Eligible patients were randomized ...

When given commonly asked questions regarding breast cancer, ChatGPT’s answers were incorrect a quarter of the time and often provided fake references. A study found that ChatGPT 3.5, when asked 20 ...

“Identifying the HER2 0 tumors that are actually ultralow will require dedicated effort and amendment of current pathology practices.” Chemotherapy plus trastuzumab and pertuzumab followed by ...

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability. HER2-positive breast cancer ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer ...

9月13至17日，欧洲肿瘤内科学会（ESMO）年会在西班牙巴塞罗那盛大召开。会上，众多专家学者竞相展示肿瘤学领域的最新研究成果，共同推动肿瘤学科的全球发展。多项来自中国学者的学术成果在本次大会首次亮相，其中，由北京大学肿瘤医院沈琳教授担任主要 ...

The Food and Drug Administration (FDA) has approved Kisqali (ribociclib) with an aromatase inhibitor for the postsurgical treatment of patients with hormone receptor (HR)-positive, HER2-negative stage ...

It may also cause fewer side effects, Teplinksy said. The expanded approval is for patients with HR-positive, HER2-negative breast cancer, the most common form of the disease. It's for stage two ...

The development of mAbs targeting growth factor receptors is one of the major advances in BC treatment. These antibodies mainly target EGFR/HER and vascular endothelial growth factor (VEGF).

The potential to treat GEA by targeting HER2 was confirmed in 2010 when researchers showed that adding Roche’s Herceptin to chemotherapy extended OS from 11.1 months to 13.8 months. There were ...